Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion


Cite item

Full Text

Abstract

Aim. To estimate the parameters of glucose metabolism and to assess the secretion of incretins in patients after biliopancreatic diversion (BPD) for morbid obesity (MO) in the early and late postoperative periods. Subjects and methods. The prospective part of the investigation included 22 patients with a body mass index of 35.8 to 68.4 kg/m2 and type 2 diabetes mellitus (T2DM). All the patients were examined before, 3 weeks and 3 months after BPD. The retrospective part covered 23 patients who were examined after BPD for MO; the postoperative period was 4.7 [2.3; 7.2] years. A control group consisted of 22 healthy, normal weight volunteers. A 75-g oral glucose tolerance test was carried out in all the groups to study the levels of glucose, immunoreactive insulin (IRI), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon at 0, 30, 60, and 120 min. Results. T2DM patients showed improvement in glucose metabolism just 3 weeks after BPD; following 3 months, they had normalized fasting blood glucose levels (5.6 [5.0; 6.0] mmol/l). During 3 months, glycated hemoglobin decreased from 7.5 [6.6; 8.5] to 5.7 [5.3; 5.9]%. In the early period following BPD, there was an increase in basal and postprandial GLP-1 levels associated with the peak IRI concentration. In the late period after BPD, the enhanced secretion of IRI and GLP-1 persisted, which was followed by a reduction in postprandial glucose levels in 4 of the 23 patients. Conclusion. T2DM remission does not depend on weight loss in the early period after BPD. In this period, the significant improvement of glucose metabolic parameters in patients with obesity and T2DM is associated with elevated GLP-1 levels. The altered incretin response is a stable effect of BPD and remains in its late period.

References

  1. Jankovic D, Wolf P, Anderwald C et al. Prevalence of endocrine disorders in morbidly obese patients and the effect of bariatric surgery on endocrine and metabolic parameters. Obes Surg. 2012;22(1):62-69. doi: 10.1007/s11695-011-0545-4
  2. Schinner S, Kempf K, Overmann H et al. Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. Exp Clin Endocrinol Diab. 2008;116(Suppl 1):S64-69. doi: 10.1055/s-2008-1081490
  3. Vinciguerra F, Baratta R, Farina M et al. Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease Acta Diabetol. 2013; 50(3): 443-449. doi: 10.1007/s00592-013-0460-3
  4. Cummings D, Overduin J, Foster-Schubert K et al. Role of the bypassed pro ximal intestine in the antidiabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109-115. doi: 10.1016/j.soard.2007.02.003
  5. Rubino F, Gagner M, Gentileschi P et al. The early effect of Roux-en-Y gastric bypass on hormones is involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242. doi: 10.1097/01.sla.0000133117.12646.48
  6. Dixon J, O’Brien P, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316-323. doi: 10.1001/jama.299.3.316
  7. Buchwald H, Estok R, Fahrbach Ket al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256. doi: 10.1016/j.amjmed.2008.09.041
  8. Яшков Ю.И., Ершова Е.В. «Метаболическая» хирургия. Ожирение и метаболизм. 2011;3:65-68. doi: 10.14341/2071-8713-4831
  9. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М.: Дипак; 2010.
  10. Дедов И.И., Яшков Ю.И., Ершова Е.В. Инкретины и их влияние на течение сахарного диабета 2 типа у пациентов с морбидным ожирением после бариатрических операций. Ожирение и метаболизм. 2012;2:3-10. doi: 10.14341/omet201223-10
  11. Вaggio L, Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157. doi: 10.1053/j.gastro.2007.03.054
  12. Fukase N, Manaka H, Sugiyama K et al. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetologia. 1995;32:165-169. doi: 10.1007/bf00838486
  13. Jones I, Owens D, Luzio S et al. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(9):668-677. doi: 10.1007/bf00274255
  14. Шестакова Е.А. Изучение факторов, влияющих на секрецию инкретинов, у лиц с различными нарушениями углеводного обмена: Дис. ... канд. мед. наук. М.: ФГБУ ЭНЦ; 2014.
  15. Faerch K, Vaag A, Holst J et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008;51:853-861. doi: 10.1007/s00125-008-0951-x
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-е издание. Под ред. Дедова И.И., Шестаковой М.В. М.; 2015.
  17. IDF taskforce on the epidemiology and prevention, 2011.
  18. Falkén Y, Hellström P, Holst J and Näslund E. Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides. J Clin Endocrinol Metab. 2011;96(7):2227-2235. doi: 10.1210/jc.2010-2876
  19. Korner J, Bessler M, Inabnet W et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3:597-601. doi: 10.1016/j.soard.2007.08.004
  20. Promintzer-Schifferl M, Prager G, Anderwald C et al. Effects of gastric bypass surgery on insulin resistance and insulin secretion in nondiabetic obese patients. Obesity (Silver Spring). 2011;19:1420-1426. doi: 10.1038/oby.2011.92
  21. Reed M, Pories W, Chapman W et al Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. J Clin Endocrinol Metab. 2011;96:2525-2531. doi: 10.1210/jc.2011-0165
  22. Umeda L, Silva E, Carneiro G et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21:896-901. doi: 10.1007/s11695-011-0412-3
  23. Laferrere B, Teixeira J, McGinty J et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-2485. doi: 10.1210/jc.2007-2851
  24. Patti M, McMahon G, Mun E et al. Severe hypoglycaemia postgastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;48:2236-2240. doi: 10.1007/s00125-005-1933-x
  25. Service G, Thompson G, Service F et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353:249-254. doi: 10.1056/nejmoa043690
  26. Goldfine A, Mun E, Devine E et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007;92:4678-4685. doi: 10.1210/jc.2007-0918
  27. Vidal J, Nicolau J, Romero F et al. Long-term effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab. 2009;94:884-891. doi: 10.1210/jc.2008-1620
  28. Swarbrick M, Stanhope K, Austrheim-Smith I et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51(10):1901-1911. doi: 10.1007/s00125-008-1118-5
  29. Scavini M, Pontiroli A, Folli F. Asymptomatic hyperinsulinemic hypoglycemia after gastric banding. N Engl J Med. 2005;353:2822-2823. doi: 10.1056/nejmc052356
  30. Мазурина Н.В., Огнева Н.А., Яшков Ю.И., Трошина Е.А., Мельниченко Г.А. Развитие гипогликемических состояний после билиопанкреатического шунтирования по поводу морбидного ожирения: клинический случай. Ожирение и метаболизм. 2013;3:44-49. doi: 10.14341/2071-8713-3864

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies